Clinical Trial: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Study Status: Completed
Recruit Status: RECRUITING
Condition: Pancreas Neoplasm
Study Type: INTERVENTIONAL
Official Title: A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2
Brief Summary:
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.
Read more